An accomplished patent litigation attorney, Wanda D. French-Brown is creative, analytical and able to focus on the overall picture to develop litigation strategies that align with her clients’ business objectives.
She represents clients in a range of technologies, including biotechnology, medical devices, healthcare diagnostics, and pharmaceuticals with a concentration in Hatch-Waxman litigation.
With a decade of experience working as a registered pharmacist in the healthcare and pharmaceutical fields, Wanda is well-versed in Food and Drug Administration guidelines created by the Hatch-Waxman and Biologics Price Competition and Innovation acts, which are crucial to the entry of generic and biosimilar pharmaceutical products.
Wanda counsels pharmaceutical clients about the scope and coverage of patents, new drug product exclusivity and litigation strategies related to Paragraph IV certifications filed under the Hatch-Waxman Act.
- Represented an American pharmaceutical company in Hatch-Waxman ANDA patent litigation involving its Sprycel® brand kinase inhibitor products. The court adopted proposed constructions for all 15 terms in dispute. The case resulted in a favorable settlement for the client. Bristol Myers Squibb Co. v. Apotex (D.N.J.)
- Represented an international based pharmaceutical company in a patent litigation involving Polymerase chain reaction (PCR) diagnostic testing kits.
- Represented a British pharmaceutical company in patent infringement litigation involving its Paxil® brand antidepressant products, which resulted in a favorable settlement.
- Represented a British pharmaceutical company in Hatch-Waxman ANDA patent litigation involving formulation patents covering its branded topical corticosteroid products.
- Represented a Japanese pharmaceutical company in Hatch-Waxman ANDA patent litigation involving formulation patents covering its branded cholesterol-lowering products.
- Represented a leading multinational technology corporation in defense of patent infringement and won summary judgment of invalidity where, after an unfavorable re-examination decision on patent validity, all defendants except the client settled out of the case.
- Rutgers, The State University of New Jersey, BS, College of Pharmacy
- Seton Hall University School of Law, JD, Intellectual Property Law Concentration, Impact Litigation (Appellate) Clinic, magna cum laude
- New Jersey
- New York
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the District of New Jersey
- New York Intellectual Property Law Association
- American Bar Association: Intellectual Property Section
- New York City Bar Association
- Minorities in the Profession Committee (2015-Present)
- Diversity Pipeline Initiatives Committee (2013-2014)
- New Jersey Intellectual Property Law Association
Rate : $$$$